A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

NCT07294508 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

706

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 + Breast Cancer

Interventions

DRUG: HLX87 + HLX22
DRUG: HLX87 + Pertuzumab
DRUG: T-Dxd + Pertuzumab
DRUG: THP

Sponsor

Shanghai Henlius Biotech